Ann Rheum Dis: Is rheumatoid arthritis targeted therapy really effective? Patient Queue Longitudinal Analysis (RA BIODAM)

The study aims to explore whether the goal of targeting (
T2T) strategies in dailyclinicalpractice can lead to more patients with rheumatoid arthritis (
RA) to achieve remission goalsa disease activity assessment of disease activity every3,
months for patients withRAwho start/
replacement of conventional synthetic or biological disease improvement anti-rheumatic drugs from10 countries for a total of2
years (
RA BIODAM queue (joint damage biomarker) Each visit is determined to target 44 activity score (
DAS44 ) (
DAS44 1.6 ) under the T2T strategy The persistent T2T is defined as a T2T that has been followed more than 2 consecutive times The main outcome was the subsequent follow-up of 3
months, which reached DAS44 mitigation Other outcomes were based on 28 activity scores for joint diseases -
blood (
DAS28-ESR ), Clinical Disease Activity Index (
CDAI ), Simplified Disease Activity Index (
S DAI) and /
of the American Society of Rheumatology and the European Union against Rheumatology (
ACR/EULAR ) definition of relief The correlation between T2T and mitigation was tested in the broad estimation equation model included 571 patients in , with a total of 4,356 visits (average (
SD ) age: 56 (
13 ) years, 78 %) for women 59 % of visits found that T2T were properly applied march months T2T (
vs no t2T ) the possibility of relief of the AS44 (
OR (
95 % 26 ): 1.03 (
0.92-1.16 ), but the continuing T2T makes the possibility of DAS44 mitigation (1.
19 Similar results were observed using DAS28-ESR mitigation For more stringent definitions (
CDAI , SDAI , and ACR/EULAR ) T2T are always positively correlated with mitigation (
OR range: 1.16-1.29 ) and persistent T2T have a more significant impact on mitigation (
OR range: 1.49-1.52 ) in routine clinical practice, the correct application of T2T strategies (especially persistent T2T ) to patients with RA leads to higher remission rates